HCAR2 Antikörper (AA 200-228)

Produktnummer ABIN5536145

Produktdetails anti-HCAR2 Antikörper

Target: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Bindungsspezifität: AA 200-228

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser HCAR2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Aufreinigung: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This NIACR1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 200-228 amino acids from the Central region of human NIACR1.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: For WB starting dilution is: 1:1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.5 mg/mL

Buffer: Supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Details zu HCAR2

Target: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Andere Bezeichnung: NIACR1 (HCAR2 Produkte)

Synonyme: GPR109A antikoerper, HCA2 antikoerper, HM74a antikoerper, HM74b antikoerper, NIACR1 antikoerper, PUMAG antikoerper, Puma-g antikoerper, Gpr109a antikoerper, Gpr109b antikoerper, HM74 antikoerper, Hcar2 antikoerper, PUMA-G antikoerper, Pumag antikoerper, mHM74b antikoerper, HCAR2 antikoerper, HCAR3 antikoerper, hydroxycarboxylic acid receptor 2 antikoerper, HCAR2 antikoerper, Hcar2 antikoerper, LOC527744 antikoerper

Hintergrund: NIACR1 acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.

Molekulargewicht: 42 kDa

Gen-ID: 338442

UniProt: Q8TDS4